896 A PHASE III, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY OF ORAL ALEDRONATE, 70 MG ONCE-A-WEEK, FOR THE PREVENTION OF ANDROGEN DEPRIVATION BONE LOSS IN NON-METASTATIC PROSTATE CANCER. A CANADIAN UROLOGY RESEARCH CONSORTIUM STUDY

✍ Scribed by Klotz, Laurence; McNeil, Irene; Kebabdjian, Marlene; Zhang, Liying; Chin, Joseph

• Book ID: 122604741
• Publisher: Lippincott Williams and Wilkins
• Year: 2011
• Tongue: English
• Weight: 45 KB
• Volume: 185
• Category: Article
• ISSN: 0022-5347
• DOI: 10.1016/j.juro.2011.02.2605